Institutional members access full text with Ovid®

Share this article on:

Endolymphatic hydrops perspectives 2012

Pierce, Nathan E.; Antonelli, Patrick J.

Current Opinion in Otolaryngology & Head and Neck Surgery: October 2012 - Volume 20 - Issue 5 - p 416–419
doi: 10.1097/MOO.0b013e328357a6c8
HEARING SCIENCE AND VESTIBULAR MEDICINE: Edited by Rodney C. Diaz and Mohamed A. Hamid

Purpose of review Endolymphatic hydrops remains a significant cause of morbidity secondary to vertigo, hearing loss, and tinnitus. The purpose of this report is to summarize the most clinically relevant publications on endolymphatic hydrops over the past 2 years.

Recent findings Hydrops has historically been a diagnosis of exclusion, but recent efforts has shown a role for MRI with intratympanic gadolinium. Cochrane reviews of intratympanic dexamethasone and gentamicin found inadequate level 1 evidence to support their use.

Summary High-level evidence to guide therapy is lacking. MRI holds potential for definitive diagnosis.

From the Department of Otolaryngology, University of Florida, Gainesville, Florida, USA

Correspondence to Patrick J. Antonelli, MD, Department of Otolaryngology, University of Florida, Box 100264, 1600 SW Archer Road, Gainesville, FL 32610-0264, USA. Tel: +1 352 273 5199; fax: +1 352 392 6781; e-mail:

© 2012 Lippincott Williams & Wilkins, Inc.